Skye C. Mayo, MD, MPH, FACS, FSSO

Associate Professor of Surgery, Division of Surgical Oncology

Oregon Health & Science University (OHSU)

Medical Director of Regional Therapy, Knight Cancer Institute at OHSU

Co-Chair, Clinical Research and Review Committee for Knight Cancer Institute

Dr. Skye C. Mayo, MD, MPH, is an Associate Professor of Surgical Oncology at Oregon Health & Science University (OHSU) and the Knight Cancer Institute in Portland, Oregon. He is board certified in both Complex General Surgical Oncology and in General Surgery having completed a surgical residency at Johns Hopkins and a surgical oncology fellowship at Memorial Sloan Kettering. His clinical practice serves patients with cancers of the liver, bile ducts, gallbladder, and pancreas. He founded and serves as the Director of the Hepatic Arterial Infusion (HAI) Program and the Medical Director of Regional Therapy at the OHSU Knight Cancer Institute. His research focuses on development of early phase clinical trials for patients with cancers of the liver and bile ducts, including intrahepatic cholangiocarcinoma and metastatic colorectal cancer to the liver. He is the Principal Investigator on two investigator-initiated trials in HAI for patients with cholangiocarcinoma, serves as the site investigator for several consortium and cooperative group hepatobiliary oncology trials, and is the national SWOG Champion for the EA2222 PUMP trial (NCT 05863195). He is the Co-Chair of the Knight Cancer Institute Clinical Research Review Committee charged with providing peer review of the scientific merit of all cancer related research studies to be conducted at OHSU. He has an active basic science collaboration with scientists in the Knight Cancer Institute. Through this collaboration he mentors several residents a year in his research efforts toward the early detection of recurrent cancer and monitoring responses to treatment in patients with colorectal cancer metastatic to the liver, cholangiocarcinoma, and pancreatic cancer. He is currently is a candidate for a Fellowship of the Academy of Wilderness Medicine (FAWM) with anticipated completed in December 2024.